Ex vivo biomarkers: functional tools to guide targeted drug development and therapy.
Most of the currently utilized predictive biomarkers for therapeutic decision-making provide information regarding the presence or absence of the drug target but reveal little about the functional circuitry of the signaling network that the drug must also impact. Ex vivo biomarkers are dynamic molecular markers evoked from living tumor cells after removal from the patient. Such ex vivo biomarkers provide valuable mechanistic information that may facilitate drug development and guide the clinical selection of targeted therapeutics.
Clark
Douglas P
DP
Department of Oncology, The Johns Hopkins School of Medicine, Johns Hopkins Hospital, Baltimore, MD 21287, USA. dclark@jhmi.edu
D014408:Biomarkers, Tumor / Q000378:metabolism*; D003657:Decision Making; D015195:Drug Design; D019008:Drug Resistance, Neoplasm; D019337:Hematologic Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism; D015398:Signal Transduction / Q000502:physiology
D014408:Biomarkers, Tumor